| 1 |
2022 |
A Novel Marine Pyran-Isoindolone Compound Enhances Fibrin Lysis Mediated by Single-Chain Urokinase-Type Plasminogen Activator. |
FGFC1 |
| 2 |
2022 |
Platelet-targeted thrombolysis for treatment of acute ischemic stroke. |
BBB, ICH, MCAO, tPA |
| 3 |
2021 |
Bioinspired In Vitro Brain Vasculature Model for Nanomedicine Testing Based on Decellularized Spinach Leaves. |
--- |
| 4 |
2020 |
Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury. |
ISALI, PA, PFC, tPA |
| 5 |
2018 |
Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury. |
ISALI, sctPA |
| 6 |
2014 |
Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. |
--- |
| 7 |
2012 |
Factor seven activating protease (FSAP): does it activate factor VII? |
FSAP, FVII |
| 8 |
2011 |
Direct chromogenic substrate immuno-capture activity assay for testing of factor VII-activating protease. |
CI, FSAP, FSAP, MRI, SNP |
| 9 |
2010 |
Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets. |
uPA |
| 10 |
2010 |
The cyclopentapeptide plactin enhances cellular binding and autoactivation of the serine protease plasma hyaluronan-binding protein. |
PHBP |
| 11 |
2009 |
Effect of recombinant single-chain urokinase-type plasminogen activator on experimental pulmonary embolism. |
CO, mPAP, PTE, rt-PA |
| 12 |
2009 |
Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits. |
alphaM, PFs, TCN |
| 13 |
2009 |
Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. |
RBC, suPAR |
| 14 |
2008 |
Factor VII-activating protease in patients with acute deep venous thrombosis. |
CRP, DVT, FSAP, FVII, FVIIa |
| 15 |
2007 |
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. |
I/R, LMW |
| 16 |
2007 |
Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis. |
--- |
| 17 |
2005 |
Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. |
EC, hr-sMTf, LRP, uPA, uPAR |
| 18 |
2005 |
Thrombolytic agents. |
SAK, tPA |
| 19 |
2004 |
High-level scu-PA production by butyrate-treated serum-free culture of recombinant CHO cell line. |
--- |
| 20 |
2004 |
Novel human plasma proteins, IHRP (acute phase protein) and PHBP (serine protease), which bind to glycosaminoglycans. |
ECM, ITI, MMPs, PHBP |
| 21 |
2003 |
Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator. |
--- |
| 22 |
2003 |
The kringle stabilizes urokinase binding to the urokinase receptor. |
ATF, GFD, HBS, suPAR, WT |
| 23 |
2002 |
Effects of inhaled plasminogen activator on the balance between coagulation and fibrinolysis in traumatized pigs. |
--- |
| 24 |
2002 |
Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension. |
PPH |
| 25 |
2002 |
[Characterization of urokinase type plasminogen activator modified by phenylglyoxal]. |
--- |
| 26 |
2002 |
[Single-chain urokinase-type plasminogen activator (scu-PA) purification by immuno-affinity chromatography]. |
KLH |
| 27 |
2001 |
Basic principles in thrombolysis: regulatory role of plasminogen. |
TAFI |
| 28 |
2001 |
Coronary artero-venous gradient of endogenous urokinase. |
tcu-PA, uPA |
| 29 |
2001 |
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). |
APMA |
| 30 |
2001 |
Identification of the epidermal growth factor-like domains of thrombomodulin essential for the acceleration of thrombin-mediated inactivation of single-chain urokinase-type plasminogen activator. |
EGF, TM |
| 31 |
2001 |
Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA). |
ARDS, MMD |
| 32 |
2000 |
Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system. |
EACA, uPA |
| 33 |
2000 |
The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells. |
HUVEC, uPA |
| 34 |
1999 |
Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment. |
NTF, uPAR |
| 35 |
1999 |
Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. |
DIC |
| 36 |
1999 |
Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. |
AMI, AUC, BASE, HMW |
| 37 |
1999 |
Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation. |
PAI-3, tcu-PA, uPAR |
| 38 |
1998 |
Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. |
suPAR |
| 39 |
1998 |
Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo. |
SMC, uPAR |
| 40 |
1998 |
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). |
uPAR |
| 41 |
1998 |
The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin. |
ATIII |
| 42 |
1997 |
Relationship between preinfarction angina and time interval to reperfusion with thrombolytic therapy in acute myocardial infarction. |
CK, LVEDVI, LVEF, MI, TIMI |
| 43 |
1996 |
A sensitive bioimmunoassay for thrombin-cleaved two-chain urokinase-type plasminogen activator in human body fluids. |
BIA |
| 44 |
1996 |
Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure. |
--- |
| 45 |
1996 |
Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. |
rscuPA, rt-PA |
| 46 |
1996 |
Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors. |
PAI-1, tPA |
| 47 |
1996 |
Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? |
ACT, CPB, TAT |
| 48 |
1996 |
Secretory production of recombinant urokinase-type plasminogen activator-annexin V chimeras in Pichia pastoris. |
aa, AOX1, IU, MPR, PL |
| 49 |
1995 |
A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group. |
--- |
| 50 |
1995 |
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase. |
--- |
| 51 |
1995 |
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas. |
ATF, uPA |
| 52 |
1995 |
Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. |
PSA, uPA |
| 53 |
1995 |
Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass. |
CPB, tcu-PA |
| 54 |
1994 |
Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C). |
--- |
| 55 |
1994 |
Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. |
GPI, tcu |
| 56 |
1994 |
Design and evaluation of a thrombin-activable plasminogen activator. |
--- |
| 57 |
1994 |
[Development of new thrombolytic substances]. |
r-PA |
| 58 |
1994 |
[Pro-urokinase for infarct therapy]. |
tcu-PA |
| 59 |
1993 |
Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator. |
HMW, LMW |
| 60 |
1993 |
Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction. |
tPA |
| 61 |
1993 |
Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. |
--- |
| 62 |
1993 |
Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator. |
NGF-gamma, PAGE |
| 63 |
1993 |
Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. |
tPA |
| 64 |
1993 |
Regulation of scu-PA secretion and u-PA receptor expression in osteoblast-like cells. |
cAMP, dbcAMP, PKC, PMA |
| 65 |
1993 |
Role of the glycosaminoglycan component of thrombomodulin in its acceleration of the inactivation of single-chain urokinase-type plasminogen activator by thrombin. |
TM |
| 66 |
1993 |
The tissue plasminogen activator finger domain confers fibrin-dependent enhancement of catalytic activity to single-chain urokinase-type plasminogen activator. |
tPA |
| 67 |
1993 |
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). |
rt-PA, tPA |
| 68 |
1992 |
Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. |
rscu-PA |
| 69 |
1992 |
Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA). |
sct-PA, tPA |
| 70 |
1992 |
Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. |
EC |
| 71 |
1992 |
In vivo and in vitro interaction of high and low molecular weight single-chain urokinase-type plasminogen activator with rat liver cells. |
--- |
| 72 |
1992 |
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man. |
tPA |
| 73 |
1992 |
Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen. |
--- |
| 74 |
1992 |
The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made. |
tPA |
| 75 |
1992 |
The rationale of prevention of thrombosis by enhancing blood levels of single-chain urokinase-type plasminogen activator (scuPA). |
--- |
| 76 |
1992 |
Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits. |
HPAs, tPA |
| 77 |
1992 |
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. |
--- |
| 78 |
1992 |
Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator "in vitro" and in a perfused rabbit heart model. |
EGF |
| 79 |
1991 |
Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. |
--- |
| 80 |
1991 |
An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. |
DEF, scuPA-AA |
| 81 |
1991 |
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. |
rscu-PA, rt-PA, tPA |
| 82 |
1991 |
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction. |
rt-PA |
| 83 |
1991 |
Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. |
AMI, tcu-PA |
| 84 |
1991 |
Hybrid molecules: insights into plasminogen activator function. |
tPA |
| 85 |
1991 |
Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro. |
PAI-1, tcu-PA |
| 86 |
1991 |
Monoclonal antibodies monospecific to single-chain urokinase-type plasminogen activator (scu-PA). |
mAbs, UK |
| 87 |
1991 |
Mutations affecting the activity of urokinase-type plasminogen activator. |
--- |
| 88 |
1991 |
Optimization of pro-urokinase secretion from recombinant Saccharomyces cerevisiae. |
RQ |
| 89 |
1991 |
Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. |
dansyl-EGRck, DFP |
| 90 |
1990 |
Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. |
--- |
| 91 |
1990 |
Interventions in acute myocardial infarction. |
APSAC or anistreplase, MI, tPA |
| 92 |
1990 |
Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. |
rt-PA |
| 93 |
1990 |
Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu). |
rtcu-PA |
| 94 |
1989 |
Assay method for single-chain urokinase-type plasminogen activator. |
--- |
| 95 |
1989 |
Comparison of thrombolytic agents: selected hematologic, vascular and clinical events. |
APSAC, rt-PA, SK, UK |
| 96 |
1989 |
Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody. |
--- |
| 97 |
1989 |
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis. |
rt-PA |
| 98 |
1989 |
[Plasminogen activators as thrombolytic agents in myocardial infarction]. |
APSAC, tPA |
| 99 |
1988 |
A sequence-dependent monoclonal antibody specific for single-chain urokinase. |
Acm |
| 100 |
1988 |
Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. |
tPA |
A Search Service for Abbreviation / Long Form
